Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc 99m methionine
- Development stage
- Unknown
- Lead developer
- Defence Research and Development Organisation
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium Tc 99m methionine (also known as 99mTc-methionine or 99mTc-MDM) is an indigenously developed single-photon emission computed tomography (SPECT) radiopharmaceutical. It is designed as a cost-effective alternative to carbon-11 methionine ([11C]MET) positron emission tomography (PET) imaging. The tracer consists of methionine conjugated to a chelator (such as DTPA) and labeled with technetium-99m. It is primarily transported into cells via the L-type amino acid transporter 1 (LAT1), which is overexpressed in various cancers. Technetium Tc 99m methionine is being clinically evaluated for the detection, grading, and differentiation of tumor recurrence from radiation necrosis in patients with glioma, as well as for the imaging of breast cancer and head and neck cancers.
- Other names
- 99mTc-methioninebis-methionine-DTPAtechnetium Tc 99m bis-methionine-DTPAtechnetium Tc 99m DTPA-bis(methionine)technetium-99m methioninetechnetium99m methioninetechnetium 99m methionine
02
Targets
SLC7A5 (Large neutral amino acid transporter small subunit 1)
Beyond the preview
Go deeper on technetium Tc 99m methionine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc 99m methionine.